Clinical development of a PSMA-Vδ2 bispecific T cell engager in metastatic castrate resistant prostate cancer

Conference

This ASCO-GU conference abstract describes the early clinical development of LAVA-1207, a PSMA-directed bispecific gamma-delta T cell engager evaluated in metastatic castration-resistant prostate cancer.